CD163 and neoplasm: Immunostaining using CD68/iNOS (markers for pro-inflammatory macrophages) and CD68/CD163 (markers for anti-inflammatory macrophages) supported these findings with high infiltration of pro-inflammatory macrophages in the tumor islets together with low infiltration of anti-inflammatory TAMs being associated with improved NSCLC patients' survival (69).